🇺🇸 Beta-3 Agonists, Adrenergic in United States

FDA authorised Beta-3 Agonists, Adrenergic on 28 June 2012

Marketing authorisations

FDA — authorised 28 June 2012

  • Application: NDA202611
  • Marketing authorisation holder: APGDI
  • Local brand name: MYRBETRIQ
  • Indication: TABLET, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Beta-3 Agonists, Adrenergic in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Beta-3 Agonists, Adrenergic approved in United States?

Yes. FDA authorised it on 28 June 2012; FDA has authorised it.

Who is the marketing authorisation holder for Beta-3 Agonists, Adrenergic in United States?

APGDI holds the US marketing authorisation.